Effect of Screening with the Fecal Immunochemical Test on Colorectal Cancer Outcomes

Biennial screening is associated with 34% fewer advanced CRC cases and 40% fewer CRC-related deaths.

Several countries around the world, and some healthcare organizations in the U.S., employ fecal immunochemical testing (FIT) for programmatic large-scale screening for colorectal cancer (CRC). In this study, investigators in Taiwan report the incidence of advanced-stage CRC (stage II or higher) and CRC-related mortality among 3 million older adults (age range, 50–69) who underwent FIT screening (offered biennially) from 2004 to 2009 and were followed through 2014. About half of the cohort underwent ≥2 screenings.

Compared with an unscreened cohort of 2.3 million similar people, screened individuals had lower incidence of advanced-stage CRC (48 vs. 76 per 100,000 person-years) and lower CRC-related mortality (20 vs. 41 per 100,000 person-year…

Reviewing Author

Charles J. Kahi, MD, MS

Disclosures

Grant/Research SupportU.S. Department of Veterans Affairs (VA) HSR&D; VA Cooperative Studies Program; VA QUERI

Editorial BoardsClinical Gastroenterology and Hepatology; AGA Perspectives

Charles J. Kahi, MD, MS

Disclosures

Grant/Research SupportU.S. Department of Veterans Affairs (VA) HSR&D; VA Cooperative Studies Program; VA QUERI

Editorial BoardsClinical Gastroenterology and Hepatology; AGA Perspectives

Effect of Screening with the Fecal Immunochemical Test on Colorectal Cancer Outcomes

Topics

Reviewing Author